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Ovarian carcinoma (OC) is a leading cause of death among women throughout the world. A number of cancer-associated genes
have been shown to be inactivated by hypermethylation of CpG islands during tumorigenesis. We tested the hypothesis that
methylation status of MGMT, CDH1, RAR-b and SYK could be important in the ovarian tumorigenic process and can lead to the
gene(s) inactivation. Therefore, we assessed the promoter hypermethylation of MGMT, CDH1, RAR-b and SYK in 43 ovarian granulosa
cell tumours (GCTs) (adult type) using methylation-specific PCR. These tumours are relatively rare, accounting for approximately 3%
of all ovarian cancers. Hypermethylation of MGMT (in 14 tumours), CDH1 (in nine tumours), RAR-b (in eight tumours) and SYK (in
seven tumours) have been found. Selective loss of RAR-b and RAR-b2 mRNA has been found in seven patients, while that of MGMT
and SYK in three patients who also show aberrant methylation in promoter region of RAR-b in addition to MGMT, SYK and CDH1
genes. Promoter CpG hypermethylation may be an alternative to mutation(s) to inactivate tumour suppressor genes such as MGMT,
CDH1, RAR-b and SYK, and this can also be an early event in the pathogenesis of OCs. Moreover, hypermethylation of the MGMT and
CDH1, MGMT and RAR-b and CDH1 and RAR-b promoters occurred concordantly (Po 0.001, 0.0421 and 0.0005 respectively;
Fischer’s exact test). In addition to this, monosomy 22 and trisomy 14 have also been found in 10 tumours. It is clear from the results
that hypermethylation of the promoter region of these tumour suppressor genes, monosomy 22 and trisomy 14, may be critical steps
in the tumorigenesis, which consequently play a permissive role for tumour aggressiveness. All these events might play an important
role in the early clinical diagnosis of the disease. Our results, therefore, suggest a potential role for epigenetic modification of these
critical tumour suppressor genes in pathways relevant to the transformation and differentiation of rare type of ovarian cancer (GCTs).
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Ovarian tumours are relatively common, and are the most lethal
tumour of the female genital tract (Evan et al, 1999). Among
ovarian cancers, granulosa cell tumours (GCTs) are relatively rare,
accounting for approximately 3% of all ovarian cancers. The
aetiology of these GCTs remains unclear. It is now accepted that
accumulation of multiple genetic aberrations can lead to the
development of most carcinomas. DNA replication errors
(RER) have been detected in epithelial ovarian cancer, as well as
in other human cancer types, and a DNA mismatch repair
deficiency may be involved in their development and or
progression (Suzuki et al, 2000). Genetic or epigenetic alterations
in a variety of genes are fundamental to the processes of growth,
cell proliferation, differentiation and programmed cell death
and removal. Each alteration may be mediated through
gross chromosomal changes and, hence, has the potential
to be detected cytogenetically (Sandberg, 1991). It is generally
thought that the events causing the activation of certain oncogenes
and/or inactivation of tumour suppressor genes lead to tumour
development and progression, which is caused by genetic
alterations such as chromosome deletions and or loss of function
mutations in the coding regions (in CpG sites) of the tumour
suppressor genes.
O
6-methylguanine-DNA methyltransferase (MGMT; 10q26; Gen-
Bank Accession No. U95038) is a DNA repair gene, which removes
methyl groups as well as larger adducts at O
6 of guanine. The
alkylation of DNA at O
6 position of guanine is associated with the
formation of DNA mutations in cancers. CpG islands within  249
to þ259 relative to transcriptional start site were chosen to study
the role of promoter methylation on gene silencing. Methylation of
MGMT gene has been reported in various carcinomas such as
gliomas, non-small-cell lung carcinoma, lymphoma, head and neck
carcinoma and colorectal cancers (Esteller et al, 1999b, 2000; Rosas
et al, 2001). E-cadherin is an Mr 120000 transmembrane
glycoprotein (16q22.1; GenBank Accession No. D49685) expressed
on the surface of epithelial cells and is essential for the
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smaintenance of normal tissue homeostasis and architecture
(Takeichi, 1995). Reduced E-cadherin expression has been
associated with an unfavourable prognosis of cancers originating
from breast, lung, nasopharynx, bladder and gastric mucosa
(Zheng et al, 1999; Garcia del Muro et al, 2000; Heimann et al,
2000), and the important mechanism for loss of expression is
methylation of the 50 CpG islands within the promoter, which
results in transcriptional repression of the gene (Yoshiura et al,
1995). CpG island in exon 1 of E-cadherin gene ( 126 to þ144)
relative to transcription start site was selected to detect the
promoter methylation effects on gene silencing. Retinoic acid
receptor beta (RAR-b;3p24.3-24.2) induces local chromatin
changes at levels of target genes containing retinoic acid
responsive elements (RAREs) by recruiting multiprotein com-
plexes with histone acetyltransferase (HAT) and histone deacety-
lase (HDAC) activities that dynamically alter chromatin structure
and regulate gene expression (Chambon, 1996). A RARE is also
located in the RAR-b promoter region and mediates RAR-b
induction in response to RA in several cell lines and tissues (de
The et al, 1990). Auto regulation of the RAR-b gene may play a
critical role in amplifying the RA response. Lack of RAR-b
expression has been observed in a number of malignant tumours,
including carcinomas of the lung (Gebert et al, 1991), head and
neck (Lotan et al, 1995) and breast (Seewaldt et al, 1995). The
overexpression of RAR-b induced growth arrest and apoptosis in
oral cancer cell lines, and could function as a tumour suppressor
(Hayashi et al, 2001). For RAR-b gene, methylation primers were
designed as per the gene sequence (position 773–1007; transcrip-
tion start site at position 844) to investigate the role of promoter
hypermethylation in gene silencing. SYK gene (9q22; GenBank
Accession No. Z29630) encodes a protein tyrosine kinase, Syk,
which is highly expressed in haematopoietic cell, especially in T-
cell and B-cell development and activation (Chu et al, 1998). Loss
of Syk expression seems to be associated with malignant
phenotype, such as increased motility and invasion (Coopman
et al, 2000). Exon 1 (107bp) and exon 2 (448bp) are separated by
B4.1kb intron and the transcription start site is located in exon 2.
CpG island spans from 350bp 50 of exon 1 to 150bp of intron 1. A
600bp region around exon 1 contains 62 CpG sites. Therefore, the
high density of CpG sites in the 50-regulatory region suggested that
promoter methylation may influence the transcriptional regulation
of SYK expression. Methylation-specific primers were chosen to
cover nine CpG numbered 17–21 (forward) and 47–50 (reverse),
whereas unmethylation-specific primers covered eight CpGs
numbered 18–22 (forward) and 35–37 (reverse). Methylation of
CpG sites in the promoter region has become recognised as an
alternative mechanism for the inactivation of certain tumour
suppressor genes, which is thought to be the most common
mechanism of gene inactivation in various tumours.
Therefore, all these above findings led us to investigate the role
of promoter hypermethylation of MGMT, CDH1, RAR-b and SYK
genes, and mRNA expression of RAR-b and RAR-b2 genes in GCTs
of ovaries.
MATERIAL AND METHODS
The subjects were 43 patients affected with GCTs of ovaries
without a positive family history. All of them were untreated at the
time of the study. The tumour grading is as follows: 19 FIGO stage
IA, 10 FIGO stage IB and 14 FIGO stage IC. All these diagnoses
were reviewed by a gynaecologic pathologist, and the tumours
were assessed using standard criteria (Russel and Bannatyne,
1989). An informed consent was taken from all the subjects prior
to the study. This study was approved by the Health Research
Ethics Board of the Faculty of Natural Sciences. In all, 25 G-banded
metaphases were obtained after a 5-day-old culture of an overnight
collagenase disaggregated specimen of the tumour.
Methylation-Specific PCR (MSP)
DNA methylation patterns in CpG islands of tumour suppressor
genes MGMT, CDH1, RAR-b and SYK were determined by
chemical modification with sodium bisulphite. Briefly, 1mg DNA
was denatured by NaOH (50ml, final concentration, 0.2M) for
10min at 371C; 1mg of salmon sperm DNA (Sigma) was added as
carrier before modification. Freshly prepared 30ml of hydroqui-
none (10mM, Sigma) and 520ml of sodium bisulphite (3M, pH 5.0,
Sigma) were mixed and the samples were incubated under mineral
oil at 551C for 16h. The DNA samples were desalted through
Wizard columns (Promega, Madison, WI, USA), then desulpho-
nated by NaOH (final concentration, 0.3 M) treatment for 5min at
room temperature, followed by ethanol precipitation. DNA was
resuspended in water and used immediately or stored at  201C.
PCR primers that distinguish between these methylated and
unmethylated DNA sequences were used. Primer sequences of all
genes for both the methylated and the unmethylated form,
annealing temperatures and the expected PCR product sizes are
summarised in Table 1. For PCR amplification, 2ml of bisulphite-
modified DNA was added in a final volume of 25ml of PCR mixture
containing 1 PCR buffer, MgCl2, deoxynucleotide triphosphates,
and primers (100pmol each per reaction) and 1U of AmpiTaq
Gold (Applied Biosystems, NJ, USA). Amplification was carried out
in a 9700 Perkin–Elmer thermal cycler under the following
conditions: 951C for 10min; 35 cycles of 951C for 45s, the specific
Table 1 Summary of primer sequences, annealing temperature and PCR product sizes used for MSP
S. no. Name and type Primer sequence PCR conditions Cycles bp
1 MGMT-Met: F 50-TTT CGA CGT TCG TAG GTT TTC GC-30 951C 30s; 611C 45s; 721C 45s 35 81
R5 0-GCA CTC TTC CGA AAA CGA AAC G-3’
2 MGMT-UnM: F 50-TTT GTG TTT TGA TGT TTG TAG GTT TTT GT-3’ 951C 30s; 611C 45s; 721C 45s 35 93
R5 0-AAC TCC ACA CTC TTC CAA AAA CAA AAC A-3’
3 CDH1-Met: F 5’-TGT AGT TAC GTA TTT ATT TTT AGT GGC GTC-30 951C 30s; 641C 30s; 721C 30s 40 112
R 5’-CGA ATA CGA TCG AAT CGA ACC G-30
4 CDH1-UnM: F 50-TGG TTG TAG TTA TGT ATT TAT TTT TAG TGG CGT C-3’ 951C 30s; 621C 30s; 721C 30s 40 120
R5 0-ACA CCA AAT ACA ATC AAA TCA AAC CAA A-30
5 RARb-Met: F 50-GGT TAG TAG TTC GGG TAG GTT TTA TC-3’ 951C 30s; 581C 30s; 721C 30s 35 235
R5 0-CCG AAT CCT ACC CCG ACG-30
6 RARb-UnM: F 50-TTA GTA GTT TGG GTA GGG TTT ATT-30 951C 30s; 581C 30s; 721C 30s 35 233
R5 0-CCA AAT CCT ACC CCA ACA-30
7 SYK-Met: F 5’-CGA TTT CGC GGG TTT CGT TC-30 951C 30s; 671C 30s; 721C 30s 35 243
R 5’-AAA ACG AAC GCA ACG CGA AAC-3’
8 SYK-UnM: F 5’-ATT TTT GTG GGT TTT GTT TGG TG-30 951C 30s; 671C 30s; 721C 30s 35 140
R5 0-ACT TCC TTA ACA CAC CCA AAC-3’
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sannealing temperature for each gene for 1min, and 721C for 60s;
followed by a final 10min extension at 721C. Following sequencing,
the primer pair was used to amplify bisulphite-modified DNA-
containing gene for E-cadherin : (forward) 50-GTT TAG TTT TGG
GGA GGG GTT-30 and (reverse) 50-ACT ACT ACT CCA AAA ACC
CAT AAC TAA-30. The PCR cycle consisted of initial denaturation
at 951C for 5min, 30 cycles (951C 30s, 501C 30s and
721C 30s) followed by a final extension at 721C for 5min. The
PCR product was then diluted 1:50 with sterile distilled water and
2ml of this 1:50 diluted product was then used for nested PCR
using methylated and unmethylated primer pairs. Similarly, the
following sequencing primer pair was used to amplify bisulphite-
modified DNA-containing gene for SYK: (forward) 50-GAT TAA
GAT ATA TTT TAG GGA ATA TG-30 and (reverse) 50-CAC CTA
TAT TTT ATT CAC ATA ATT TC-30. The PCR cycle consisted of
hot start at 951C 5min and 35 cycles (951C 45s, 581C 50s
and 721C 45s) followed by a final extension at 721C for
5min. The PCR product was then diluted 1:50 with sterile
distilled water and 2ml of this 1:50 diluted product was then
used for nested PCR using methylated and unmethylated
primer pairs. Each PCR product (10ml) was directly loaded onto
6% nondenaturing polyacrylamide gels, stained with ethidium
bromide and directly visualised under UV illumination. The MSP
for all samples was repeated twice to confirm their methylation
status.
Statistical differences were assessed with Fisher’s exact test by
InStat 3 Windows software. Two-sided test were used to determine
the significance. P-values less than 0.05 were regarded as
statistically significant.
RT–PCR
RAR-b and RARb-2
Total RNA was prepared using RNeasy mini-kit (Qiagen, CA, USA)
as per the manufacturer’s recommendations. In brief, total RNA
was extracted from the specific cancerous tissues. Cell lysates were
then homogenised by passing repeatedly through a 23-gauge
needle followed by spinning through a QIAshredder (Qiagen, CA,
USA). RNA concentrations were determined by measuring the
absorbance (260nm UV) using a spectrophotometer (Pharmacia).
Total RNA (2mg) was used for the generation of cDNAs using
Superscript reverse transcriptase (GIBCO BRL, Gaithersburg, MD,
USA). The following primers were used to detect RAR-b and RAR-
b2 transcripts: RAR-b forward 50-ACC AGC TCT GAG GAA CTC
GTC CCA-30 and RAR-b reverse 50-AGG CGG CCT TCA GCA GGG
TAA TTT-30, and for RAR-b2 forward (in exon 3), 50-GCA TGG
CAG AGT GCC CTA TC-30; reverse (in exon 6), 50-TCC CAG AGT
CAT CCC TGC TTC AT-30. PCR amplification was performed for
30 cycles at 951C for 30s, 601C for 30s (621C for RAR-b2) and 721C
for 45s (60s for RAR-b2). Human GAPDH was used as an internal
control.
MGMT gene
The following primer sequences were used for MGMT gene sense,
50-CCTGGCT GAATGCCTATTTC-30, and anti-sense, 50-CAG-
CTTCCATAACACCTGTCTG-30, which amplifies 116-bp PCR
product. To verify the integrity of cDNA, b2-microglobulin
expression was also analysed using the primer sequences sense,
50-CATCCAGCGTACTCCAAAGA-30, and b2-microglobulin anti-
sense, 50-GACAAGTCTGAATGCTCCAC-30, which amplifies 165-
bp PCR product. These two sets of primers span junctions between
two exons, so amplification of the contaminating genomic DNA
can be excluded. PCR amplification was performed for 941C for
10min, then 35 cycles of 941C for 45s, 571C for 60s and 721C for
30s, followed by a final elongation step at 721C for 10min.
SYK gene
The following primer sequences were used for SYK gene sense, 50-
TGTCAAGGATAAGAACATCATAG-30, and anti-sense, 50-CAC-
CACGTCAT AGTAGTAATTG-30, which amplifies 507-bp PCR
product. In this PCR, b2-microglobulin was also used as an internal
control. The optimised PCR program was 941C for 5min, then 35
cycles of 941C for 40s, 621C for 40s and 721C for 45s, followed by a
final elongation step at 721C for 7min.
The PCR products were subjected to electrophoresis in 2.0%
agarose gels and visualised by ethidium bromide staining.
RESULTS
Cytogenetic analysis performed on these tumours exhibited a
46,XX normal karyotype in 33 tumours. However, trisomy 14 and
monosomy 22 were found in only 10 tumours (Table 2).
MGMT, CDH1, RAR-b and SYK promoter
hypermethylation
The methylation status of ovarian tumours (GCTs) was determined
at the respective loci using MSP. DNA from 43 ovarian tumours
was modified using sodium bisulphite, which converts all
unmethylated cytosine residues to uracil, but leaves methylated
cytosines unchanged. To confirm that the modification was
successful, all samples were first amplified with primers specific
for unmethylated DNA at the p16 or MLH1 loci (even tumours
methylated at these loci would be expected to be positive due to
contamination with normal tissue, which is known to be
unmethylated). The samples were next subjected to MSP using
primers specific for methylated DNA at the respective loci being
studied.
At least one of these four genes showed aberrant methylation in
17 tumour samples (17 out of 43). Methylation of only one gene
was found in 13.95% (6 of 43) of tumours. The percentage of the
tumours with methylation in genes 2, 3 and 4 is 9.3% (4 of 43),
9.3% (4 of 43) and 6.97% (3 of 43), respectively (Figure 1). Three
tumours were found to be hypermethylated for four tumour
suppressor genes (Table 2) investigated in the present study. The
representative examples of MSP are shown in Figure 2.
We compared hypermethylation of MGMT, CDH1, RAR-b and
SYK promoters in ovarian carcinoma (OC). As shown in Table 3,
we found concordant hypermethylation of MGMT and CDH1
promoters (0.001), and MGMT and RAR-b promoters (0.0421).
Similarly, hypermethylation of CDH1 and RAR-b promoters
(0.0005) was also found. However, we found no correlation
between the methylation status of MGMT and SYK promoters,
CDH1 and SYK promoters or RAR-b and SYK promoters. There
was no significant correlation between the DNA methylation status
and clinical/pathological parameters with respect to age, tumour
size and pathological grading.
RT–PCR for RAR-b, RAR-b2, MGMT and SYK gene
expression study
To examine the biological role of promoter hypermethylation in
GCTs of ovaries, we assessed the levels of gene expression by
semiquantitative RT–PCR in tumours with known methylation
status in RAR-b gene. Both RAR-b and RAR-b2 were found to have
negative expression of mRNA in seven patients with OC showing
promoter hypermethylation in RAR-b gene. Another patient was
essentially negative for RAR-b2 mRNA, although it shows aberrant
methylation in the RAR-b promoter region. All other patients of
OC patients showed normal expression of both RAR-b and RAR-b2
and were not methylated (Table 2). The data suggest that promoter
hypermethylation leading to gene silencing may affect a variety of
key pathways in germ cell tumorigenesis. Aberrant promoter
methylation changes that occur in cancer are associated with
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stranscriptional repression and loss of function of the gene by
interrupting the binding of proteins involved in the transcription
activator complex. Our gene expression analysis by RT–PCR
demonstrated that all tumours that showed methylation of RAR-b
genes also showed downregulation of mRNA levels in the
methylated tumours. Thus in these cases, promoter hypermethyla-
tion is one mechanism whereby gene expression can be
deregulated in GCTs. We also assessed the levels of gene
expression in MGMT and SYK genes by semiquantitative RT–
PCRs in these patients. Only three patients showed negative
expression of mRNA in these genes. Two patients showed
promoter hypermethylation in all four tumour suppressor genes
and negative expression of mRNA in RARb, MGMT and SYK.
DISCUSSION
Monosomy 22 and trisomy 14 appear to be emerging as
nonrandom chromosome abnormalities in this type of tumours,
Table 2 Promoter hypermethylation in different genes in ovarian cancer
Promoter hypermethylation Expression of
S. no. Age (years) Stage MGMT CDH1 RAR-b SYK RAR-b RAR-b2 MGMT SYK Trisomy 14 Monosomy 22
14 5 I A + + +      + + Yes Yes
25 5 I A        + + + + No No
35 1 I A   + + + + + + No No
46 5 I A      ++ + +  No No
53 8 I A +      + + + + Yes Yes
63 6 I A +    ++ + + + N o N o
77 5 I A   +   +   + + Yes Yes
88 1 I A        + + + + No No
93 8 I A        + + + + No No
10 47 IA        + + + + No No
11 49 IA        + + + + No No
12 64 IA + + +        + Yes Yes
13 39 IA        + + + + No No
14 42 IA        + + + + No No
15 48 IA + + +      + + Yes Yes
16 53 IA        + + + + No No
17 58 IA        + + + + No No
18 61 IA + + + +       Yes Yes
19 33 IA        + + + + No No
20 52 IB        + + + + No No
21 47 IB        + + + + No No
22 51 IB        + + + + No No
23 39 IB        + + + + No No
24 49 IB        + + + + No No
25 66 IB + + + +       Yes Yes
26 62 IB        + + + + No No
27 73 IB + + +      + + Yes Yes
28 58 IB + +    + + + + No No
29 52 IB        + + + + No No
30 55 IC        + + + + No No
31 59 IC        + + + + No No
32 62 IC      ++ + + + N o N o
33 44 IC +    + + + + + Yes Yes
34 42 IC        + + + + No No
35 37 IC +      + + + + No No
36 66 IC        + + + + No No
37 69 IC +      + + + + No No
38 61 IC        + + + + No No
39 37 IC        + + + + No No
40 45 IC + + + +    + + Yes Yes
41 48 IC        + + + + No No
42 71 IC        + + + + No No
43 38 IC + +    + + + + No No
+¼hypermethylated;  ¼unmethylated; +¼mRNA expression present;  : mRNA expression lost.
% of tumours showing methylation
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Figure 1 Percentage of distribution of the number of genes methylated
in ovarian carcinoma.
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salthough it is also associated with other complex chromosome
abnormalities. In light of the data, the present finding of
monosomy 22 as the sole chromosome change in these tumours
suggests that this karyotypic change, possibly followed by the
acquisition of an extra chromosome 14 (trisomy), may be
nonrandom but an early, nonobligatory event of the tumorigenesis
of GCTs of the ovary (Dal Cin et al, 1997; Speleman et al, 1997, Van
den Berghe et al, 1999). The loss of fidelity in the inherent order of
replication of allelic pairs during cell division provides a source for
generating mutations involving genetic (aneuploidy) and epige-
netic (gene silencing or allelic inactivation) events required for the
generation and establishment of malignant phenotype (Duesberg
et al, 2000). As reported in previous studies and in the present
findings, monosomy of chromosome 22 and trisomy 14 provide a
prognostic factor for the disease (Speleman et al, 1997). This
emphasizes the association between MGMT, CDH1, SYK and RARb
methylation and aneuploidy. Genome-wide hypomethylation due
to reduced levels of DNA methyl transferase, Dnmt 1 may lead to
the loss or gain of certain chromosomes, that is, monosomy 22
and/or trisomy 14 as seen in the present study. Therefore, altered
methylation results in chromosomal instability and hence in-
creased risk of developing cancers. Instability of chromosomes is
of such fundamental importance to the development of human or
animal cancers that possibly there may be a relationship between
DNA methylation status and chromosome loss/gain in somatic
cells (Eden et al, 2003, Gandet et al, 2003).
DNA methylation is an inheritable epigenetic change in human
cancers and the transcriptional silencing by hypermethylation of
CpG islands in the promoter region is becoming more recognised
as a common mechanism for the inactivation of various tumour
suppressor genes and also affects a number of molecular pathways
in human cancer. About 50% of human genes have unmethylated
CpG clusters at their 50-regulatory sequences. Aberrant methyla-
tion or hypermethylation of CpG islands in the promoters is
associated with transcriptional inactivation and silencing of
tumour suppressor genes. DNA replication errors have been found
in ovarian GCTs (Suzuki et al, 2000). These findings further
suggest that DNA mismatch repair deficiency may also contribute
to the pathogenesis of ovarian cancer, and this deficiency may be
an early event in the development and progression of the disease.
Studies on methylation of specific genes known to play important
roles in tumour development have contributed greatly to our
current understanding of ovarian cancer. We found hypermethyla-
tion in MGMT gene in 32.5% cases of OC (14 out of 43). There are
reports in the literature regarding the promoter hypermethylation
and gene silencing of MGMT in many cancers (Esteller et al, 2000;
Rosas et al, 2001; Bae et al, 2002). We found hypermethylation in
E-cadherin gene (CDH1) in 20.9% OCs (9 out of 43). Hypermethy-
lation in CDH1 gene and its reduced expression in gut, liver,
prostate and breast cancers, which could be due to the disruption
of intercellular adhesion and impairment of b-catenin mediated
transactivation of cadherin–catenin complex (Graff et al, 1995;
Sadot et al, 1998; Tamura et al, 2000; Corn et al, 2001; Oue et al,
2002), has been reported. DNA methylation in the RAR-b promoter
region has been found in 18.6% ovarian tumours (8 out of 43).
Methylation in the promoter region of RAR-b gene is frequently
found to be associated with downregulation/loss of its expression
in tissues affected with gastric carcinoma and in gastric cell lines,
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Figure 2 Representative examples of MSP analysis of MGMT, CDH1,
RAR-b and SYK genes in GCTs of ovarian origin. (A) Unmethylated and
methylated MGMT PCR products were detected in one and three cases.
(B) Unmethylated and methylated CDH1 PCR products were detected in
one and four cases. (C) Unmethylated and methylated RAR-b products
were detected in one and four cases. (D) Unmethylated and methylated
SYK PCR products were detected in two and three cases, respectively. (E)
Gene expression of RAR-b in GCTs of ovaries (F) loss of gene expression
of MGMT gene in one patient (G) loss of gene expression of SYK gene in
one patient and (H) GADPH as internal control (þ) for expression
studies: U, unmethylated PCR products; M, methylated PCR products; Ma,
Molecular weight marker; N
þ, gene expression in lymphocytes; T
þ, gene
expression in cancerous tissue; T
 , loss of expression in cancerous tissues.
Table 3 Correlation of promoter methylation of MGMT, CDH1, RARb
and SYK in ovarian carcinomas
Methylated Unmethylated P-value
MGMT methylation status
CDH1 methylation status
Methylated 9 0 0.001*
Unmethylated 5 11
RAR-b methylation status
Methylated 7 1 0.0421*
Unmethylated 7 10
SYK methylation status
Methylated 4 2 0.6609
Unmethylated 10 9
CDH1 methylation status
RAR-b methylation status
Methylated 7 1 0.0005*
Unmethylated 2 15
SYK methylation status
Methylated 3 4 1
Unmethylated 6 11
RAR-b methylation status
SYK methylation status
Methylated 2 5 1
Unmethylated 6 12
*Significant at Po 0.05.
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shead and neck cancers, breast cancer and non-small-cell lung
carcinoma (Xu et al, 1994, 1997; Hayashi et al, 2001; Oue et al,
2002). DNA hypermethylation in SYK gene has been found in
16.3% ovarian tumours (7 out of 43). DNA methylation and loss of
SYK expression has been reported in breast cancer (Coopman et al,
2000; Yuan et al, 2001). It could be associated with DNA
hypermethylation mediated by methyl-CpG binding proteins that
bind to methylated cytosines and forms a repressive and inactive
complex of proteins that helps in repressing the transcription
including that of HDACs and are gene silencing (Wade et al, 1999).
Similar type of results have been reported for hMLH1 gene in
primary gastric cancers and endometrial cancers (Fleisher et al,
1999; Leung et al, 1999). Several genes including tumour
suppressor genes and DNA repair genes such as hMLH1, RB1,
VHL, p15, p16, RASSF1A, MGMT and BRCA1 in human cancers
(Herman et al, 1994, 1996, 1998; Merlo et al, 1995; Esteller et al,
1999a; Baldwin et al, 2000; Gras et al, 2001; Nakayama et al, 2001;
Yoon et al, 2001) were shown to be epigenetically inactivated by
DNA methylation in tumours. Hypermethylation of CpG islands of
another tumour suppressor gene RASSF1A has been reported in
ovarian and renal cell carcinoma (Yoon et al, 2001). One of the
major mechanisms of tumour progression is thought to be the
inactivation of tumour suppressor genes. This inactivation can be
induced by mechanisms such as chromosomal deletion and loss of
function mutation in the coding region of genes or by epigenetic
alteration in the form of methylation of promoter regions. We
found that 15 of the MSI-positive tumours had hypermethylation
of either p16, BRCA1 or RASSF1A gene, whereas none of the MSI-
negative tumours (MSS) demonstrated the promoter hypermethy-
lation and this could be due to the epigenetic inactivation of either
p16, BRCA1 or RASSF1A genes (unpublished data). While it is
possible that most of the methylation events we observed
contribute in some way to the carcinogenic process, it is unlikely
that all the methylated loci play a direct role in ovarian
tumorigenesis. Rather, methylation of only certain classes of
genes, such as tumour suppressor genes may be crucial to cancer
progression.
We found concordant hypermethylation in promoters of MGMT
and CDH1, MGMT and RAR-b, CDH1 and RAR-b. Retinoic acid
(RA) has profound regulatory effects in the control of many
biological processes such as development, immunomodulation,
differentiation, proliferation, reproduction and apoptosis (Lotan,
1980). The regulation of cell growth and differentiation of normal,
premalignant and malignant cells by retinoids is thought to result
from the direct and indirect effects of retinoids on gene expression.
These effects are mediated by the nuclear receptors, including
RAR-b2 located at 3p24. Retinoic acid receptor beta has four
alternative splicing forms and the b-2 form appears to possess
tumour-antagonizing activity at least in some cancers. There are
no reports of the mutations in the RAR-b gene, but it undergoes
epigenetic inactivation by promoter methylation in tumours of
different origin. Retinoic acid receptor beta underwent DNA
promoter region methylation in significant percent in several other
tumours such as lung (Virmani et al, 2000), cervical (Yang et al,
2001) bladder (Maruyama et al, 2001), and prostate (Maruyama
et al, 2002). Squamous cell carcinomas and premalignant
dysplasias demonstrate a specific downmodulation of RAR-b that
can be restored by systemic retinoid therapy (Lotan, 1995). It has
also been reported that RA induces upregulation of CDH1
expression and the morphological change of fibroblastoid to
epithelioid growth of human pancreatic cancer cell line SUIT-2
(Jimi et al, 1998). Promoter hypermethylation in three genes
MGMT, CDH1 and RAR-b together in seven cases of OC, which
also show loss of expression of both RAR-b and RAR-b2, may be
due to the involvement of the signalling pathway mediated by b-
catenin and other factors in the tumorigenic process in these OCs.
It has already been reported that the reduced expression of E-
cadherin gene and its hypermethylation (Tamura et al, 2000), and
the reduced expression of RAR-b due to the promoter hyper-
methylation may be associated with the reduced expression of
CDH1. E-cadherin is involved in a signalling pathway mediated by
b-catenin and lymphocyte enhancer factor and T cell transcription
factors and can, therefore, explain the concordant hypermethyla-
tion in the promoter regions of these three genes. Promoter
hypermethylation of RAR-b2 may block or interfere with the
retinoid signalling pathways in OC. Deregulation of this pathway
results in constant activation of b-catenin, lymphocyte enhancer
factor and T cell factor target genes, including c-myc and cyclin D1.
For the cyclin-dependent kinase inhibitor p16, the silencing of the
gene mediated by promoter hypermethylation seems to be an early
event in the development and progression of the tumorigenic
process in ovarian cancers. CpG methylation patterns are
replicated together with DNA replication during the S phase
(Stein et al, 1982), and the altered transcriptional regulation via
aberrant promoter methylation could play an important and
significant role in the tumorigenic process of these ovarian
cancers. Our results suggest promoter methylation of tumour
suppressor genes such as MGMT, CDH1 and SYK. We also
analysed the relationship between promoter methylation status
and basal expression levels of RAR-b, RAR-b2, MGMT and SYK in
GCTs of ovaries. Our data clearly show that methylation in the
promoter region of RAR-b gene is correlated with downregulation/
loss of RAR-b2 gene expression of GCTs of ovaries. Therefore, it
might be the only mechanism responsible for loss of or
downregulation of RAR-b gene expression in this type of cancer
and plays a critical role in the tumour growth and development,
which can cause disruption in the retinoid signalling pathway, the
metastasis-related process and DNA repair processes in OC.
Similarly, out of 14 patients who show promoter hypermethylation
in MGMT, three show loss of expression while out of 7 patients
who show promoter hypermethylation in SYK gene, only three
were found to have loss of expression. It is clear from these results
that it is not always true for all the tumour suppressor genes to
show a positive correlation between promoter hypermethylation
and loss of expression in cancers.
There exist two different pathways that can contribute to the
development of cancers; genome-wide hypomethylation may lead
to the loss of chromosomes thus leading to chromosomal
instability, whereas promoter methylation in certain tumour
suppressor genes, which is responsible for gene silencing, can
lead to the development of cancers in somatic cells. Therefore, the
balance in DNA methylation is very important, and alteration in
these may be protective in one pathway but deleterious in the
other. It can therefore be concluded that promoter hypermethyla-
tion of MGMT, CDH1, RAR-b and SYK genes, and loss of
expression of RAR-b and RAR-b2 in ovarian cancers (GCTs) is
relatively common and this may also be useful as a tumour marker
for early diagnosis and subsequent disease monitoring. Hence,
these epigenetic signatures could play a decisive role in designing
treatment options for this category of ovarian cancer.
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